| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,820,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile ALX Oncology Holdings is a holding company. Through its subsidiaries, Co. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on capabilities in protein engineering and oncology led by the CD47 blocker, evorpacept. Co.'s primary product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction and breast cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
12,000 |
16,400 |
16,400 |
16,400 |
| Total Buy Value |
$102,338 |
$152,109 |
$152,109 |
$152,109 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
122,000 |
138,548 |
152,059 |
158,283 |
| Total Sell Value |
$1,611,556 |
$1,856,531 |
$1,949,679 |
$2,018,581 |
| Total People Sold |
2 |
4 |
4 |
4 |
| Total Sell Transactions |
5 |
10 |
15 |
19 |
| End Date |
2024-03-28 |
2023-12-26 |
2023-06-27 |
2022-06-27 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Randolph Sophia |
Chief Medical Officer |
• • – |
2021-04-12 |
4 |
AS |
$58.06 |
$438,978 |
D/D |
(7,387) |
193,750 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-03-25 |
4 |
OE |
$0.99 |
$9,900 |
D/D |
10,000 |
561,346 |
|
- |
|
| Pons Jaume |
President and CEO |
• • – |
2021-03-22 |
4 |
AS |
$63.79 |
$1,143,860 |
D/D |
(16,700) |
551,346 |
|
- |
|
| Pons Jaume |
President and CEO |
• • – |
2021-03-22 |
4 |
OE |
$1.91 |
$31,897 |
D/D |
16,700 |
568,046 |
|
- |
|
| Randolph Sophia |
Chief Medical Officer |
• • – |
2021-03-10 |
4 |
AS |
$73.38 |
$549,173 |
D/D |
(7,387) |
201,137 |
|
- |
|
| Garcia Peter S |
Chief Financial Officer |
• – – |
2021-01-28 |
4 |
OE |
$4.08 |
$25,002 |
D/D |
6,128 |
9,128 |
|
- |
|
| Pons Jaume |
President & CEO |
• • – |
2021-01-26 |
4 |
OE |
$0.99 |
$9,900 |
D/D |
10,000 |
551,346 |
|
- |
|
| Graham G. Walmsley |
Director |
– • – |
2020-12-14 |
4 |
B |
$76.00 |
$1,520,000 |
I/I |
20,000 |
995,000 |
2.1 |
- |
|
| Plain Henry A Jr |
10% Owner |
– – • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
3,691,171 |
120,212 |
|
- |
|
| Plain Henry A Jr |
10% Owner |
– – • |
2020-07-21 |
4 |
B |
$19.00 |
$7,600,000 |
I/I |
400,000 |
22,000 |
1.5 |
- |
|
| Lettmann Jason |
Director |
– • • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
3,691,171 |
120,212 |
|
- |
|
| Lettmann Jason |
Director |
– • • |
2020-07-21 |
4 |
B |
$19.00 |
$7,600,000 |
I/I |
400,000 |
22,000 |
2.25 |
- |
|
| Lettmann Jason |
Director |
– • • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
88,704 |
107,220 |
|
- |
|
| Venbio Global Strategic Gp Ii, Ltd. |
See Remarks |
• • • |
2020-07-21 |
4 |
B |
$19.00 |
$57,000 |
D/D |
3,000 |
99,406 |
0.01 |
- |
|
| Venbio Global Strategic Gp Ii, Ltd. |
See Remarks |
• • • |
2020-07-21 |
4 |
B |
$19.00 |
$16,150,000 |
I/I |
850,000 |
5,268,325 |
0.01 |
- |
|
| Venbio Global Strategic Gp Ii, Ltd. |
See Remarks |
• • • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
7,041,969 |
4,418,325 |
|
- |
|
| Venbio Global Strategic Gp Ii, Ltd. |
See Remarks |
• • • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
78,175 |
96,406 |
|
- |
|
| Vivo Opportunity Fund, L.p. |
10% Owner |
– – • |
2020-07-21 |
4 |
B |
$19.00 |
$18,525,000 |
I/I |
975,000 |
185,526 |
1.5 |
- |
|
| Vivo Opportunity Fund, L.p. |
10% Owner |
– – • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
3,245,048 |
4,034,522 |
|
- |
|
| Hemrajani Rekha |
Director |
– • – |
2020-07-21 |
4 |
B |
$19.00 |
$57,000 |
D/D |
3,000 |
3,000 |
2.39 |
- |
|
| Pietzke Steffen |
VP Fin & Chief Acct Officer |
• – – |
2020-07-21 |
4 |
B |
$19.00 |
$57,000 |
D/D |
3,000 |
3,000 |
2.74 |
- |
|
| Graham G. Walmsley |
Director |
– • – |
2020-07-21 |
4 |
B |
$19.00 |
$18,525,000 |
I/I |
975,000 |
975,000 |
2.1 |
- |
|
| Graham G. Walmsley |
Director |
– • – |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
2,105,901 |
2,161,981 |
|
- |
|
| Goodman Corey S |
Executive Chairman |
– • • |
2020-07-21 |
4 |
A |
$0.00 |
$0 |
I/I |
7,188,585 |
54,083 |
|
- |
|
| Goodman Corey S |
Executive Chairman |
– • • |
2020-07-21 |
4 |
B |
$19.00 |
$16,150,000 |
I/I |
850,000 |
850,000 |
2.25 |
- |
|
107 Records found
|
|
Page 4 of 5 |
|
|
